Article Figures & Data
Figures
- Figure 1.
Percentage of CD115-positive cells in the peripheral blood in mice with complete response (CR), partial response (PR), and progressive disease (PD) with immune checkpoint inhibitors (ICIs) treatment.
- Figure 2.
Percentage of non-classical monocytes in the peripheral blood in mice with complete response (CR), partial response (PR), and progressive disease (PD) after immune checkpoint inhibitors (ICIs). *p=0.044 (CR vs. PD).
- Figure 3.
Percentage of classical monocytes among peripheral blood in mice with complete response (CR), partial response (PR), and progressive disease (PD) after immune checkpoint inhibitors (ICIs) treatment. *p=0.044 (CR vs. PD).
- Figure 4.
Flow cytometric analysis of monocytes after five days of culture of cells obtained from the bone marrow using the method described in the Materials and Methods. The ratio of Non-classical monocytes (NCMs) was higher than that isolated from peripheral blood. (A1-3) NCM sorting strategies. (B) CX3CR1 expression in each monocyte fraction. Darker areas in the graph indicate NCMs. The numbers indicate the percentage of CX3CR1 expression in NCMs relative to isotype. (C) CCR2 expression in monocyte fractions. Histograms showing CCR2 expression in mouse NCMs, CMs, and isotypes. Thick lines indicate NCMs.
- Figure 5.
Efficacy of immune checkpoint inhibitors (ICIs), ICIs + classical monocytes (CMs) or ICIs + non-classical monocytes (NCMs) on the MC38 C57BL/6 mice model. Tumor volume after administration of non-classical monocytes was obtained by cell sorting. None of the tumors in the control group was eradicated, one tumor was eradicated in the group treated with ICIs alone. Four tumors were eradicated in the group treated with CMs and ICIs, and six tumors were eradicated in the group treated with NCMs and ICIs. *p<0.001 (ICI vs. NCM + ICI).
- Figure 6.
Survival analyzed using the Kaplan–Meier method. CMs: Classical monocytes; NCMs: non-classical monocytes; ICIs: immune checkpoint inhibitors.
- Figure 7.
Efficacy of non-classical monocytes (NCMs) alone. NCMs were isolated as described in the Materials and Methods. NCMs were administered by tail vein on day 5.
- Figure 8.
Combined effects of immune checkpoint inhibitor with classical monocytes (CMs) derived from peripheral blood. Tumor volume measured after administration of CM. CM was sorted from peripheral blood on the day of administration. No antitumor effects were observed in the CM group.
